We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week's Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands against the other stocks.

Micro- and small-cap companies dominated the stock market last week, clocking in impressive gains on the back of a flurry of catalysts that boosted investing appetite.

We named last week’s top 10 performers that outperformed the Russell 2000 index, which dropped by 4.04 percent week-on-week. Among them, one firm particularly stood out with its outstanding 317-percent jump, thanks to a $1-billion deal that could fuel its growth prospects.

To come up with the list, we considered the stocks with the highest week-on-week change, comparing their share prices on March 7 and February 28.

We classified micro-cap companies as those with a market capitalization below $300 million and small-cap firms as those with a market capitalization below $2 billion.

A scientist at a computer station, surrounded by a neural network of artificial intelligence code.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s share price increased by 56 percent week-on-week to finish Friday at $3.37 from $2.16 on February 28 as investor sentiment was largely boosted by news that it has achieved a 33-percent enrollment for the third phase study of its BXCL501 which aims to treat agitation associated with various neuropsychiatric disorders that is affecting an estimated 23 million individuals in the US.

According to BioXcel Therapeutics, Inc. (NASDAQ:BTAI), it aims to enroll 200 patients to join the study, and it officially opened 23 clinical trial sites for the trial.

The study focuses on the lowest approved dose of IGALMI and aims to support a supplemental new drug application for label expansion in the home setting. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) expects to release the top-line data in the second half of the year.

Overall BTAI ranks 7th on our list of last week's top performers. While we acknowledge the potential of BTAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BTAI but trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

 

Disclosure: None. This article is originally published at Insider Monkey.